Catalano G, Catalano M C, Frankel Wetter R L
Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa, USA.
Clin Neuropharmacol. 1997 Aug;20(4):352-6. doi: 10.1097/00002826-199708000-00007.
Clozapine was approved by the U.S. Food and Drug Administration in 1989 for treatment of severely ill schizophrenic patients. It has activity against both the positive and negative symptoms of schizophrenia, which has made it an alternative to traditional antipsychotic medications such as haloperidol. However, clozapine must be used cautiously due to its side effect profile. These side effects include agranulocytosis, seizures, and cardiorespiratory symptoms. We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. The literature is reviewed and the treatment implications are discussed.
氯氮平于1989年被美国食品药品监督管理局批准用于治疗重症精神分裂症患者。它对精神分裂症的阳性和阴性症状均有疗效，这使其成为氟哌啶醇等传统抗精神病药物的替代品。然而，由于其副作用，氯氮平必须谨慎使用。这些副作用包括粒细胞缺乏症、癫痫发作和心肺症状。我们报告了一例患者，该患者在开始使用氯氮平后出现了多发性浆膜炎（心包积液、胸腔积液和心包炎），停用氯氮平后症状缓解。本文对相关文献进行了综述并讨论了治疗意义。
